Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

videos

Suzanne Lentszch, MD, PhD
Videos
Strategies for Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
02/13/2024
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Suzanne Lentszch, MD, PhD, discusses the management of high-risk, newly diagnosed multiple myeloma.
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Suzanne Lentszch, MD, PhD, discusses the management of high-risk, newly diagnosed multiple myeloma.
At the 2023 Lymphoma, Leukemia &...
02/13/2024
Lymphoma, Leukemia & Myeloma Network
Suzanne Lentszch, MD, PhD
Videos
Strategies for Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
02/13/2024
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Suzanne Lentszch, MD, PhD, discusses the management of high-risk, newly diagnosed multiple myeloma.
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Suzanne Lentszch, MD, PhD, discusses the management of high-risk, newly diagnosed multiple myeloma.
At the 2023 Lymphoma, Leukemia &...
02/13/2024
Lymphoma, Leukemia & Myeloma Network
Suzanne Lentszch, MD, PhD
Videos
Strategies for Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
02/13/2024
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Suzanne Lentszch, MD, PhD, discusses the management of high-risk, newly diagnosed multiple myeloma.
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Suzanne Lentszch, MD, PhD, discusses the management of high-risk, newly diagnosed multiple myeloma.
At the 2023 Lymphoma, Leukemia &...
02/13/2024
Lymphoma, Leukemia & Myeloma Network
Adriana Rossi, MD, Mount Sinai
Conference Coverage
CAR-T Cell Therapy vs Stem Cell Transplant for the Treatment of Patients With Multiple Myeloma
01/24/2024
During a debate at the 2023 Lymphoma, Leukemia & Myeloma Congress, Adriana Rossi, MD, discussed whether CAR-T therapy is more beneficial than stem cell transplant in treatment regimens among patients with multiple myeloma.
During a debate at the 2023 Lymphoma, Leukemia & Myeloma Congress, Adriana Rossi, MD, discussed whether CAR-T therapy is more beneficial than stem cell transplant in treatment regimens among patients with multiple myeloma.
During a debate at the 2023...
01/24/2024
Lymphoma, Leukemia & Myeloma Network
Adriana Rossi, MD, Mount Sinai
Conference Coverage
CAR-T Cell Therapy vs Stem Cell Transplant for the Treatment of Patients With Multiple Myeloma
01/24/2024
During a debate at the 2023 Lymphoma, Leukemia & Myeloma Congress, Adriana Rossi, MD, discussed whether CAR-T therapy is more beneficial than stem cell transplant in treatment regimens among patients with multiple myeloma.
During a debate at the 2023 Lymphoma, Leukemia & Myeloma Congress, Adriana Rossi, MD, discussed whether CAR-T therapy is more beneficial than stem cell transplant in treatment regimens among patients with multiple myeloma.
During a debate at the 2023...
01/24/2024
Lymphoma, Leukemia & Myeloma Network
Dan Vogl, MD, University of Pennsylvania
Conference Coverage
Evaluating Bispecific T-Cell Engagers for the Treatment of Patients With Multiple Myeloma
01/23/2024
During the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Dan Vogl, MD, discusses the optimal use of newly available bispecific T-cell engagers and other targets for multiple myeloma treatment.
During the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Dan Vogl, MD, discusses the optimal use of newly available bispecific T-cell engagers and other targets for multiple myeloma treatment.
During the 2023 Lymphoma,...
01/23/2024
Lymphoma, Leukemia & Myeloma Network
Dan Vogl, MD, University of Pennsylvania
Conference Coverage
Evaluating Bispecific T-Cell Engagers for the Treatment of Patients With Multiple Myeloma
01/23/2024
During the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Dan Vogl, MD, discusses the optimal use of newly available bispecific T-cell engagers and other targets for multiple myeloma treatment.
During the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Dan Vogl, MD, discusses the optimal use of newly available bispecific T-cell engagers and other targets for multiple myeloma treatment.
During the 2023 Lymphoma,...
01/23/2024
Lymphoma, Leukemia & Myeloma Network
Faith E. Davies, MD, Perlmutter Cancer Center
Conference Coverage
Choosing a Treatment Strategy for Patients With Early Relapsed Multiple Myeloma
01/22/2024
During the 2023 Lymphoma, Leukemia & Myeloma Congress, Faith E Davies, MD, discussed current treatment options for patients with early relapsed multiple myeloma.
During the 2023 Lymphoma, Leukemia & Myeloma Congress, Faith E Davies, MD, discussed current treatment options for patients with early relapsed multiple myeloma.
During the 2023 Lymphoma,...
01/22/2024
Lymphoma, Leukemia & Myeloma Network
Faith E. Davies, MD, Perlmutter Cancer Center
Conference Coverage
Choosing a Treatment Strategy for Patients With Early Relapsed Multiple Myeloma
01/22/2024
During the 2023 Lymphoma, Leukemia & Myeloma Congress, Faith E Davies, MD, discussed current treatment options for patients with early relapsed multiple myeloma.
During the 2023 Lymphoma, Leukemia & Myeloma Congress, Faith E Davies, MD, discussed current treatment options for patients with early relapsed multiple myeloma.
During the 2023 Lymphoma,...
01/22/2024
Lymphoma, Leukemia & Myeloma Network
Joseph Mikhael, MD, City of Hope Cancer Center
Conference Coverage
Strategies for Treating Patients With Multiply Relapsed Multiple Myeloma
01/19/2024
At the 2023 Lymphoma, Leukemia & Myeloma Congress, Joseph Mikhael, MD, discusses treatment regimens like CELMoDs and XP01 inhibitors for patients with multiply relapsed multiple myeloma.
At the 2023 Lymphoma, Leukemia & Myeloma Congress, Joseph Mikhael, MD, discusses treatment regimens like CELMoDs and XP01 inhibitors for patients with multiply relapsed multiple myeloma.
At the 2023 Lymphoma, Leukemia &...
01/19/2024
Lymphoma, Leukemia & Myeloma Network

Advertisement

About

For nearly 2 decades, the Lymphoma, Leukemia & Myeloma Congress (formerly the Lymphoma & Myeloma Congress) has been recognized around the world as the most respected forum for industry-leading hematologic research.

It’s where interdisciplinary specialists convene to explore the controversial and the complex, the emerging and the exciting, and discuss, debate, and discover along the way.

This program features 4 days of comprehensive learning as we analyze emerging data, discover innovative treatment methods, and get a glimpse into the future of lymphoma, myeloma, and leukemia disorders.

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use